Research
Acetyl-L-carnitine in the body: between mitochondria, neurotransmitters and cell metabolism
Acetyl-L-carnitine has mainly been studied in people who are ill. There are hardly any data for healthy people.
Acetyl-L-carnitine (ALCAR) appears on many labels for brain and energy. The studies behind it tell a different story: it has mainly been studied in illness, for example in dementia, depressive symptoms, nerve damage from diabetes or severe liver disease. There are hardly any data for healthy people.1
This article sorts the reviews by question and says how robust they are. It adds 2 questions that are rarely asked: how much of it reaches the body, and why did one large trial find more nerve damage rather than less?
What is acetyl-L-carnitine?
Carnitine is a molecule made by the body. The body maintains its supply in 3 ways: food, a modest amount of its own synthesis and the kidneys, which take back 90 to 99% of the filtered carnitine. Acetyl-L-carnitine is the form with an acetyl group attached. Among the carnitine compounds in the body, it is the most important in quantity and function.2
Carnitine carries long-chain fatty acids into the mitochondria, the power plants of the cell. There they are broken down to produce energy.3 Acetyl-L-carnitine is described as having additional properties: an action on nerve cells that use acetylcholine as a messenger, a stabilising role in cell membranes and a contribution to mitochondrial function.4 This is why research focuses above all on the brain and nerves.
How much acetyl-L-carnitine reaches the body?
From normal food, the gut absorbs 54 to 87% of the L-carnitine it contains. From food supplements of 0.5 to 6 g it is only 14 to 18%, because absorption is then mainly passive. Bacteria in the large intestine break down the rest.2
For acetyl-L-carnitine itself the data are thinner. Laboratory experiments suggest that part of it is already split in the gut wall. After 2 g daily, the blood level rose by 43%, so part of it does arrive unchanged. As the level rises, the kidneys excrete more: after an intravenous dose it was back at baseline within 12 hours.2
Well absorbed from food, poorly from capsules
Share of L-carnitine absorbed by the human gut
What do studies show on depressive symptoms?
A 2018 meta-analysis pooled 12 randomised trials with 791 participants. In 9 trials with placebo or no treatment as the comparison, depressive symptoms were lower with acetyl-L-carnitine (standardised mean difference -1.10). The individual trials, however, differed widely, and the difference was clearest in older adults.5
A 2021 umbrella review adopted this value and rated the quality of the evidence as moderate. None of the dietary factors it examined reached high quality.6 The 2022 guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) and the Canadian network CANMAT mentions acetyl-L-carnitine in its summary only for ADHD, with the verdict “not recommended”.7
What do studies show on memory and dementia?
For Alzheimer’s dementia, a Cochrane review assessed 11 trials. Early studies had shown benefits; larger, later studies did not confirm them. There was no difference from placebo in cognition, severity of dementia or daily function. Only the clinical global impression was better at 12 and 24 weeks, no longer at 52 weeks. Given the many comparisons, the authors consider a chance finding possible.4
For people without cognitive impairment, a Cochrane review found only 2 trials, both in young adults. After 3 days of L-carnitine there was no difference in reaction time, attention or memory. The authors rated the evidence as very low and could not draw any conclusion.1 In 2011 EFSA, too, found no human studies from which a contribution of acetyl-L-carnitine to normal cognitive function could be derived.8
Mood and memory: one signal, many gaps
Reviews of randomised trials, acetyl-L-carnitine compared with the control group
Veronese 2018 · 9 trials with placebo or no treatment
Xu 2021 · umbrella review
Hudson 2003 · 11 trials, Alzheimer’s dementia
Chen 2017 · 2 trials, healthy young adults
EFSA 2011 · assessment of a health claim
What do studies show in nerve damage from diabetes?
The 2019 Cochrane review found 4 trials with 907 participants, 3 of them with placebo as the comparison. On a pain scale of 0 to 100 mm, the score with acetyl-L-carnitine was on average 9.16 mm lower. The authors rate the certainty of this finding as very low. Up to 1,500 mg daily there was hardly any difference, above that a larger one, but this subgroup analysis is even less certain.3
2 of the trials were funded by a manufacturer; in the other 2, at least 1 adviser to a manufacturer was involved. Data on nerve function and sensation are largely missing. In the fourth trial, methylcobalamin, a form of vitamin B12, was the comparison; pain was not reported there.3
The research interest is based on laboratory findings on the protection and growth of nerve cells in the peripheral nervous system.3 This mechanism is not established in humans.
Why did one trial in chemotherapy find more nerve damage?
In the SWOG S0715 trial, women with breast cancer receiving taxane chemotherapy took 3,000 mg of acetyl-L-carnitine daily or placebo for 24 weeks. Less nerve damage had been expected. More was measured: at 12 weeks there was no difference yet, at 24 weeks the symptoms were worse in the acetyl-L-carnitine group. Severe nerve damage occurred in 8 women there, in 1 with placebo. 409 women were analysed.9
A systematic review of natural products for this type of nerve damage reaches the same conclusion: acetyl-L-carnitine may worsen it. For alpha-lipoic acid, its effect remained unknown there.10
Nerves: uncertain in diabetes, unfavourable in chemotherapy
Acetyl-L-carnitine compared with placebo
Rolim 2019 · Cochrane, nerve damage from diabetes
Hershman 2013 · 409 women, taxane chemotherapy
Brami 2016 · systematic review, chemotherapy
What do studies show on the liver, fatigue and fertility?
Hepatic encephalopathy is a disorder of brain function in severe liver disease. A meta-analysis pooled 7 randomised trials with 660 participants on it. With acetyl-L-carnitine, blood ammonia levels were lower and a number connection test was completed faster. Adverse effects were reported rarely and were minor.11
On fatigue in multiple sclerosis, a Cochrane review found only 1 completed trial. It compared 2 g of acetyl-L-carnitine daily with the drug amantadine. Whether carnitine affects fatigue remained unclear.12 A review of fatigue in older people with chronic illnesses lists acetyl-L-carnitine among the approaches studied, alongside physical activity, rest and sleep.13
In fibromyalgia, pain scores improved in individual trials. The trials, however, were often small and biased, and the authors see no sufficient basis for a recommendation.14 For unexplained male infertility, a meta-analysis pooled 8 randomised trials with L-carnitine and acetyl-L-carnitine. Sperm motility and shape were better, sperm count was not. In 5 trials there was no demonstrable effect on the pregnancy rate.15
Liver, fatigue, fertility: a small evidence base
Reviews, acetyl-L-carnitine compared with the control group
Jiang 2013 · 7 trials, 660 participants, hepatic encephalopathy
Tejani 2012 · 1 trial, multiple sclerosis
Lowry 2020 · fibromyalgia
Khaw 2020 · 8 trials, male infertility, with L-carnitine
Which amounts were studied, and how well were they tolerated?
The trials mostly used 1.5 to 3 g daily: 1,500 to 3,000 mg for nerve damage from diabetes, 2 g in multiple sclerosis, 3,000 mg in the chemotherapy trial.3,9,12 Study amounts are not an intake recommendation.
In one placebo-controlled trial on diabetic neuropathy, 6 of 147 participants taking more than 1,500 mg daily stopped because of adverse effects, compared with 2 of 147 in the placebo group. Headache, abnormal sensations in the face and gastrointestinal complaints were reported. The Cochrane authors consider the data too uncertain to judge safety.3 Nothing can be derived from this about use outside these study conditions, particularly over long periods.
In certain contexts - during chemotherapy, for instance - supplementation should be examined critically.9
Is there an authorised health claim for acetyl-L-carnitine?
No. In the EU, foods may only be advertised with authorised health claims, and there is none for acetyl-L-carnitine. In 2011 EFSA assessed the contribution to normal cognitive function. There were no human studies from which conclusions could be drawn; a cause and effect relationship was not established.8 How the procedure works is explained in the article on EU health claims.
Who do these studies apply to?
The studies cited concern predominantly clearly defined clinical groups: people with Alzheimer’s dementia, with depressive symptoms, with nerve damage from diabetes or chemotherapy, with hepatic encephalopathy. Questions like these belong in medical care.
These results cannot be transferred to healthy people.
Why is acetyl-L-carnitine in combination products?
In combination products, acetyl-L-carnitine is usually justified by its role in energy metabolism - the same justification usually carries coenzyme Q10 there too - along with presumed interactions with B vitamins and antioxidants. The basis for this justification is missing: what has been tested is almost exclusively single substances.
What does it mean on balance?
Acetyl-L-carnitine is well understood in metabolism but thinly supported in humans. The clearest signals come from small, inconsistent trials in people who are ill: depressive symptoms and ammonia levels in severe liver disease. In dementia and in healthy people there was no robust benefit, in nerve damage from diabetes a very uncertain one, and in chemotherapy a disadvantage.
Key takeaways
- Acetyl-L-carnitine is the most important carnitine compound in the body. From food supplements the gut absorbs only 14 to 18% of the L-carnitine.
- For depressive symptoms, scores were lower in trials; the quality of the evidence is rated moderate, and the trials are inconsistent.
- In Alzheimer’s dementia and in healthy people there was no robust difference in cognition or memory.
- In nerve damage from diabetes the finding is very uncertain; in a large chemotherapy trial, nerve damage was worse with acetyl-L-carnitine.
- There is no authorised health claim in the EU; combination effects are barely studied.
Sources
- Chen N et al. L-carnitine for cognitive enhancement in people without cognitive impairment. Cochrane Database Syst Rev, 2017.
- Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci, 2004.
- Rolim LC et al. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev, 2019.
- Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev, 2003.
- Veronese N et al. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosom Med, 2018.
- Xu Y et al. Role of dietary factors in the prevention and treatment for depression: an umbrella review of meta-analyses of prospective studies. Transl Psychiatry, 2021.
- Sarris J et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry, 2022.
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to acetyl-L-carnitine and contribution to normal cognitive function (ID 1432) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 2011.
- Hershman DL et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol, 2013.
- Brami C et al. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review. Crit Rev Oncol Hematol, 2016.
- Jiang Q et al. Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann Hepatol, 2013.
- Tejani AM et al. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev, 2012.
- Torossian M, Jacelon CS. Chronic Illness and Fatigue in Older Individuals: A Systematic Review. Rehabil Nurs, 2021.
- Lowry E et al. Dietary Interventions in the Management of Fibromyalgia: A Systematic Review and Best-Evidence Synthesis. Nutrients, 2020.
- Khaw SC et al. l-carnitine and l-acetylcarnitine supplementation for idiopathic male infertility. Reprod Fertil, 2020.
ATLAS All-in-One - 35 ingredients, 4 capsules, once a day.
